SCHEMBL10185254

SCHEMBL10185254

O=C(NCCNC(=O)c1cccc(Oc2ccc(C(F)(F)F)cc2)c1)c1ccc(O[C@H]2CC[C@@H](C(=O)O)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.50
EPHX2 P34913 2/20 0.47
NPC1 O15118 1/20 0.46
RAF1 P04049 1/20 0.45
GCGR P47871 1/20 0.45
PKM P14618 1/20 0.44
SCN9A Q15858 1/20 0.44
F10 P00742 1/20 0.43
RAB9A P51151 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
MMP2 P08253 1/20 0.43
CA9 Q16790 1/20 0.43
DGAT1 O75907 1/20 0.42
SLC5A7 Q9GZV3 1/20 0.42
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10186147 0.92 NPC1 (0.54) NPC1PKMF10RAB9ACA12
SCHEMBL10185255 0.90 NPC1 (0.47) EPHX2NPC1PKMSCN9AF10
SCHEMBL10185060 0.90 ALDH1A1 (0.52) MAPK14ACSL1ALDH1A1POLB
SCHEMBL10186138 0.89 EPHX2 (0.53) MAPK14EPHX2GCGRDGAT1
SCHEMBL10186421 0.87 EPHX2 (0.52) MAPK14EPHX2GCGRF10DGAT1
SCHEMBL10185122 0.86 CA12 (0.56) RAB9ACA12CA1CA2MMP2
SCHEMBL10185162 0.84 MTNR1B (0.51) EPHX2F10CA12CA1CA2
SCHEMBL10184899 0.83 RAB9A (0.54) NPC1F10RAB9ACA1CA2
SCHEMBL664114 0.82 DGAT1 (0.56) NPC1RAB9ADGAT1LMNAMEN1
SCHEMBL10184323 0.82 DGAT1 (0.56) NPC1RAB9ADGAT1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 MAPK14 3989/4885EPHX2 1718/4885NPC1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.